FOLH1 and Renal insufficiency: The development of highly selective PSMA ligands is a challenging task due to the close sequence similarity between PSMA and other glutamate carboxypeptidases.[22] For instance, GCP3 (a PSMA anti‐target) is a transmembrane protein expressed in healthy tissues (e.g., kidneys and salivary glands) that shares 83% sequence similarity with PSMA.[22] This overlap can cause cross‐reactivity of glutamate‐based PSMA ligands such as Pluvicto and may lead to their accumulation in kidney and salivary glands and contribute to side effects such as xerostomia and renal insufficiency.[21, 47]